Ignite Creation Date:
2024-05-06 @ 3:09 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04539236
Status:
RECRUITING
Last Update Posted:
2023-10-02
First Post:
2020-08-31
Brief Title:
Luspatercept and Lenalidomide L2 in Lower-risk Non-del5q MDS Patients
Sponsor:
Mikkael Sekeres MD
Organization:
University of Miami
Study Overview
Official Title:
A Multicenter Phase IbII Study That Combines Luspatercept and Lenalidomide L2 in Lower-risk Non-del5q MDS Patients
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate if the combination of drugs Lenalidomide and Luspatercept will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome MDS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CASE2920 | OTHER | Case Comprehensive Cancer Center | None |